Eli Lilly to buy Morphic for $3.2 b in cash to expand integrin therapies
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.
HQ Team June 13, 2023: Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental.
Indian billionaire Azim Premji's private equity and venture capitalist arm, Premji Invest, and Tube Investments, together will acquire Lotus Surgicals for INR 3.8.
Redx Pharma, based in the UK and Jounce Therapeutics, US, will merge in an all-share transaction worth $425 million to establish a new.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com